undamentalytics Newsletter
Sign in

Corbus Pharmaceuticals Holdings, Inc. key statistics and ratios

In fiscal 2022, Corbus Pharmaceuticals Holdings, Inc. had return on equity of -83.0%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 2022
Net margin<−999%<−999%<−999%<−999%−197.7%<−999%<−999%—
Return on equity−98.5%—−97.2%−130.5%——−79.8%−83.0%
Return on assets−68.7%−130.0%−76.4%−97.7%−148.7%−147.0%−43.5%−48.7%
R&D as % of revenue908.2%807.6%>999%>999%247.9%>999%>999%—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

8 /100

Weak moat

How hard Corbus Pharmaceuticals Holdings's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -62.9% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -1240.2%; its worst year was -20990.2%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -729.7% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 647.7% over five years; stock-based pay has been a median 153.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Corbus Pharmaceuticals Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Corbus Pharmaceuticals Holdings, Inc.